Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Sine United Medicinal Herbs, was ordered to pay a a total penalty 165.8 million yuan for violating the anti-monopoly law, according to a Hong Kong Stock Exchange disclosure on Saturday.
The Shanghai Municipal Administration for Market Regulation said Sine United Medicinal Herbs and its operators made monopoly agreements for the neostigmine methylsulfate injection.
The penalty includes the forfeited illegal income of 115.5 million yuan and a fine of 10% of its 2023 revenue. The fine was mitigated by 80%, resulting in an actual penalty of 50.3 million yuan.
The forfeited income and fine totaled 165.8 million yuan.
The regulator also ordered the pharmaceutical company to cease its illegal acts, the disclosure said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。